Literature DB >> 12942537

Survivin study: what is the next wave?

Fengzhi Li1.   

Abstract

Survivin, a novel member of inhibitor of apoptosis (IAP) protein family, is aberrantly expressed in cancer but undetectable in normal, differentiated adult tissues. Current studies suggest that survivin is implicated in both control of apoptosis and regulation of cell division. However, due to some inconsistent observations on survivin subcellular localization, there is debate about survivin's function in regulating apoptosis, cell division, or both. This review will discuss concepts, experimental methods, and interesting results that unify the different notions about survivin localization and function or point out gaps of knowledge about controversial issues. The author also intends to review various aspects of survivin studies, which were not emphasized or sufficiently discussed in previous reviews on survivin, and update recent developments that may reveal new applications of disease-oriented therapeutics in the coming years. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942537     DOI: 10.1002/jcp.10327

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  105 in total

1.  Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections.

Authors:  José Vassallo; Talal Al Saati; Randy D Gascoyne; Kathyrn Welsh; John C Reed; Pierre Brousset; Georges Delsol
Journal:  J Hematop       Date:  2010-01-30       Impact factor: 0.196

2.  Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system.

Authors:  Xavier Coumoul; Wenmei Li; Rui-Hong Wang; Chuxia Deng
Journal:  Nucleic Acids Res       Date:  2004-06-15       Impact factor: 16.971

3.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

4.  Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter.

Authors:  Qiuying Cheng; Xiang Ling; Andrew Haller; Takahito Nakahara; Kentaro Yamanaka; Aya Kita; Hiroshi Koutoku; Masahiro Takeuchi; Michael G Brattain; Fengzhi Li
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

5.  Poriferan survivin exhibits a conserved regulatory role in the interconnected pathways of cell cycle and apoptosis.

Authors:  B Luthringer; S Isbert; W E G Müller; C Zilberberg; N L Thakur; G Wörheide; R H Stauber; M Kelve; M Wiens
Journal:  Cell Death Differ       Date:  2010-07-23       Impact factor: 15.828

6.  Survivin is a potential mediator of prostate cancer metastasis.

Authors:  Min Zhang; John J Coen; Yoshiyuki Suzuki; Michael R Siedow; Andrzej Niemierko; Li-Yan Khor; Alan Pollack; Yifen Zhang; Anthony L Zietman; William U Shipley; Arnab Chakravarti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

7.  Survivin and escaping in therapy-induced cellular senescence.

Authors:  Qin Wang; Peter C Wu; Rachel S Roberson; Belinda V Luk; Iana Ivanova; Elizabeth Chu; Daniel Y Wu
Journal:  Int J Cancer       Date:  2010-05-25       Impact factor: 7.396

8.  Human ovarian tissue vitrification/warming has minor effect on the expression of apoptosis-related genes.

Authors:  Maasoume Abdollahi; Mojdeh Salehnia; Saghar Salehpour; Nassim Ghorbanmehr
Journal:  Iran Biomed J       Date:  2013

Review 9.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

10.  Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition.

Authors:  Satoshi Mamori; Tadashi Asakura; Kiyoshi Ohkawa; Hisao Tajiri
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.